Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
Emergence Therapeutics has raised $98.1M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Emergence Therapeutics's investors include RA Capital Management, Bpifrance, HTGF (High-Tech Gruenderfonds), NRW.BANK, OrbiMed.
Emergence Therapeutics is headquartered in Duisburg, Germany.
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
Emergence Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Emergence Therapeutics — Funding & Investors." VCBacked, December 7, 2021, https://www.vcbacked.co/company/emergence-therapeutics. Accessed August 14, 2026.
VCBacked. (2021). Emergence Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/emergence-therapeutics
{{cite web |title=Emergence Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/emergence-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated